Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.

Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG, Gainetdinov RR.

PLoS Biol. 2005 Aug;3(8):e271. Epub 2005 Aug 2.

2.

Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.

Greenamyre JT.

J Neural Transm Gen Sect. 1993;91(2-3):255-69. Review.

PMID:
8099800
3.

Pharmacological treatment with L-DOPA may reduce striatal dopamine transporter binding in in vivo imaging studies.

Nikolaus S, Antke C, Hautzel H, Mueller HW.

Nuklearmedizin. 2016;55(1):21-8. doi: 10.3413/Nukmed-0764-15-08. Epub 2015 Dec 7. Review.

PMID:
26642370
4.
5.

[A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].

Nishi K, Kondo T, Narabayashi H.

No To Shinkei. 1987 Jul;39(7):663-72. Review. Japanese.

PMID:
3314916
6.

[Behavioral and pharmacological characteristics of mice lacking the dopamine transporter].

Biala G.

Postepy Hig Med Dosw (Online). 2004;58:560-4. Review. Polish.

7.

Peculiarities of L: -DOPA treatment of Parkinson's disease.

Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.

Amino Acids. 2005 Mar;28(2):157-64. Epub 2005 Mar 9. Review.

PMID:
15750845
8.

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

Olanow CW, Obeso JA, Stocchi F.

Lancet Neurol. 2006 Aug;5(8):677-87. Review.

PMID:
16857573

Supplemental Content

Support Center